Trial Profile
Combined Treatment of Adenoid Cystic Carcinoma With Cetuximab and IMRT Plus C12 Heavy Ion Boost - ACCEPT - (ACC, Erbitux, and Particle Therapy); Phase I/II Feasibility Study.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 25 Feb 2020
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary)
- Indications Adenoid cystic carcinoma; Head and neck cancer
- Focus Adverse reactions
- Acronyms ACCEPT
- 01 Jan 2020 Results published in the International Journal of Radiation Oncology, Biology, Physics
- 14 Feb 2019 Status changed from recruiting to discontinued.
- 23 Apr 2013 Planned end date changed from 1 Oct 2015 to 1 Jul 2017 as reported by ClinicalTrials.gov.